Effects of the Cannabinoid-1 Receptor Antagonist/Inverse Agonist Rimonabant on Satiety Signaling in Overweight People with Schizophrenia: A Randomized, Double-Blind, Pilot Study

Ítems similars

• Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia: A Randomized, Double-Blind, Pilot Study
  per: Kelly, Deanna L., et al.
  Publicat: (2011)
• Rimonabant for Neurocognition in Schizophrenia: A 16-Week Double Blind Randomized Placebo Controlled Trial
  per: Boggs, Douglas L., et al.
  Publicat: (2011)
• Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys
  per: Schindler, Charles W, et al.
  Publicat: (2016)
• Apparent Inverse Relationship between Cannabinoid Agonist Efficacy and Tolerance/Cross-Tolerance Produced by Δ(9)-Tetrahydrocannabinol Treatment in Rhesus Monkeys
  per: Hruba, Lenka, et al.
  Publicat: (2012)
• Hemopressin is an inverse agonist of CB(1) cannabinoid receptors
  per: Heimann, Andrea S., et al.
  Publicat: (2007)